#35 Veterinary pharmacovigilance part 2 – James Mount

Drug Safety Matters

Content provided by Uppsala Monitoring Centre. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Uppsala Monitoring Centre or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

4M ago 41:42

MP3•Episode home

Human and veterinary pharmacovigilance (PV) share many goals, challenges and approaches. But there are also significant differences, such as the numerous animal species that veterinary PV needs to take into account. In this two-part episode of Drug Safety Matters, James Mount, Veterinary Pharmacovigilance assessor at the Swedish Medical Products Agency, and EU elected chair of the Pharmacovigilance Working Party for veterinary medicinal products, joins the show to talk about veterinary PV practice and its differences and similarities to human PV.

Tune in to find out

How the types of ADRs reported for animals and humans differ
How the many species and breeds included in veterinary PV affect the ADR coding
What the Veterinary Big Data Strategy is

... and much more!

Want to know more?

The public portal of the European Union Veterinary Pharmacovigilance Database.
One Health – an integrated approach to the well-being of people, animals and the environment.
A survey of veterinary professionals in Sweden, about practices and attitudes in relation to ADR reporting.
A review of adverse events in animals and children after secondary exposure to transdermal hormone-containing medicines.
The EMA Big Data strategy for veterinary medicines and Data quality framework for medicines regulation
Small Animal Veterinary Surveillance Network (SAVSNET) - University of Liverpool
VetCompass - Royal Veterinary College, RVC
Veterinary good pharmacovigilance practices (VGVP) | European Medicines Agency (EMA)
Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) | European Medicines Agency (EMA)

Join the conversation on social media
Follow us on Facebook, LinkedIn, X, or Bluesky and share your thoughts about the show with the hashtag #DrugSafetyMatters.
Got a story to share?
We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!
About UMC
Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.

Chapters

1. #35 Veterinary pharmacovigilance part 2 – James Mount (00:00:00)

2. Intro (00:00:14)

3. Welcome (00:01:00)

4. Types of ADRs reported in veterinary vs human PV (00:01:18)

5. User safety – when humans are accidentally exposed to veterinary medicines (00:02:41)

6. When animals are accidentally exposed to human medicines (00:06:33)

7. Gentamicin – an illustrative example of the overlap between human and veterinary PV (00:08:46)

8. Differences in ADR reporting between the veterinary and human side (00:10:03)

9. Environmental aspects in veterinary PV (00:13:27)

10. Vet PV's diversity in stakeholders, target groups and patients (species, breeds) (00:16:18)

11. Listener question: differences in susceptibility to certain ADRs between different breeds (and species) (00:19:04)

12. Technological solutions for discovering ADRs in animals? (00:23:52)

13. Signal detection in veterinary PV practice (00:26:44)

14. The EU Veterinary Big Data Strategy (00:29:54)

15. AI in PV in the near future (00:35:44)

16. Outro (00:40:15)

54 episodes

#Science #Fitness #Biology #Medicine #Natural Sciences #Uppsala Monitoring Centre #Drug Safety #Healthcare #Medicines Safety #Patient Safety #Pharmacovigilance #Effect